Additional file 8: of Clinical significance of FBXO17 gene expression in high-grade glioma

Figure S6. Correlation of FBXO17 gene expression with MGMT methylation status in the TCGA cohort. The statistical significance was assessed by Mann-Whitney test. (PDF 65 kb

Additional file 5: of Clinical significance of FBXO17 gene expression in high-grade glioma

Table S2. Univariate and Multivariate Models for Overall Survival in Patients with GBM in the TCGA Cohort while including MGMT methylation status as a covariate*. (DOCX 24 kb

Additional file 6: of Clinical significance of FBXO17 gene expression in high-grade glioma

Figure S4. Correlation of FBXO17 mRNA expression with GBM transcriptional subtypes in the TCGA cohort. (PDF 59 kb

Additional file 3: of Clinical significance of FBXO17 gene expression in high-grade glioma

Table S1. The top 50 most significantly correlated genes with survival in the TCGA cohort. (DOCX 25 kb

Additional file 7: of Clinical significance of FBXO17 gene expression in high-grade glioma

Figure S5. (a) Kaplan-Meier OS curves for patients in the TMZ group after classifying patients into two groups based on MGMT status. (b) Kaplan-Meier OS curves for patients in the non-TMZ group after classifying patients into two groups based on MGMT status. (PDF 46 kb

Additional file 4: of Clinical significance of FBXO17 gene expression in high-grade glioma

Figure S3. Correlation of FBXO17 mRNA expression with survival within grade IV glioma patients alone, respectively, (a) in GSE4271 and (b) in GSE4412. The one-third patients with the least FBXO17 expression were categorized into FBXO17 low group and the rest of patients were categorized into FBXO17 high group. (PDF 113 kb

Additional file 1: of Clinical significance of FBXO17 gene expression in high-grade glioma

Figure S1. Patient ages in the data sets that are included in this study. (PDF 36 kb